SCHEMBL8284750

SCHEMBL8284750

Cc1cc(C)c2nc(NCC(C)O)n(Cc3nc(C)ccc3O)c2c1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.38
▸ USP2 O75604 2/20 0.38
▸ HPGD P15428 2/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ LMNA P02545 6/20 0.38
▸ SMN1; SMN2 Q16637 4/20 0.38
▸ ALDH1A1 P00352 5/20 0.35
▸ POLB P06746 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ PCSK9 Q8NBP7 2/20 0.33
▸ GFER P55789 1/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ TSPO P30536 1/20 0.30
▸ RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4281670 0.90 KDM4E (0.36) KDM4EUSP2HPGDHSD17B10SMN1; SMN2
SCHEMBL8283679 0.85 KDM4E (0.39) KDM4EUSP2HPGDHSD17B10ALDH1A1
SCHEMBL14003034 0.85 KDM4E (0.39) KDM4EUSP2HPGDHSD17B10ALDH1A1
SCHEMBL4284545 0.83 KDM4E (0.37) KDM4EUSP2HPGDHSD17B10LMNA
SCHEMBL8285627 0.81 KDM4E (0.33) KDM4EUSP2HPGDHSD17B10ALDH1A1
SCHEMBL13932114 0.80 KDM4E (0.43) KDM4EUSP2HPGDHSD17B10ALDH1A1
SCHEMBL4286685 0.79 TSPO (0.36) KDM4EHSD17B10LMNAALDH1A1MAPK1
SCHEMBL4288001 0.78 LMNA (0.40) KDM4EHPGDHSD17B10LMNAALDH1A1
SCHEMBL8284613 0.78 KDM4E (0.41) KDM4EUSP2HPGDHSD17B10LMNA
SCHEMBL4280686 0.77 P2RX3 (0.34) KDM4EALDH1A1GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005058870-A1 AMINO-BENZIMIDAZOLES DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION TIBOTEC PHARMACEUTICALS LTD. (IE) 2005-06-30 — — WO disclosed
Send feedback